NEW YORK, May 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0552779/Global-Endometriosis-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 32 companies including many key and niche players such as Abbott Laboratories, AEterna Zentaris, Inc., AstraZeneca Plc, Bayer HealthCare Pharmaceuticals, Inc., Eli Lilly and Company, Meditrina Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., and Repros Therapeutics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Endometriosis Fact Sheet II-1
A Quick Market Primer II-1
Poor Efficacy and Safety Profiles of Existing Drugs Lead to
Huge Unmet Medical Needs II-2
Market Scenario II-2
Potential Drugs II-2
The Pipeline Review II-3
Market Outlook II-3
2. TREATMENT OF ENDOMETRIOSIS II-4
Endometriosis & Available Treatment Options II-4
Endometriosis Treatment: In a Nutshell II-5
I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) II-5
II. Hormonal Therapy II-6
Gonadotropin Releasing Hormone (Gnrh) Agonists II-6
Select Major GnRH-Agonists for Endometriosis Treatment II-6
Lupron, Zoladex and Synarel - The Major Drugs II-7
Add-back Medication II-8
Promising GnRH-antagonist Under Pipeline II-8
Elagolix II-8
Progestogens II-9
Select Major Progestins for Endometriosis Treatment II-10
Combined Oral Contraceptive Pill II-11
Danazol and Other Suppressive Steroids II-11
Chinese Herbs - More Effective than Danazol or Gestrinone II-11
Aromatase Inhibitors II-12
III. Non-hormonal Therapy II-12
Anti-angiogenic Agents II-12
Selective COX-2 Inhibitors II-12
TNF-alpha Inhibitors II-12
IV. Surgical Techniques II-12
V. Complementary Therapies II-13
Long-term Approach to Pain II-13
Lifestyle Modifications II-13
Chinese Herbs II-13
Emerging Treatment for Endometriosis Treatment II-13
Treatment for Endometriosis-related Infertility II-14
Hormonal Treatment II-14
Minimal to Mild Endometriosis II-14
Moderate-Severe Endometriosis II-15
Surgical Treatment II-15
Minimal-Mild Endometriosis II-15
Moderate-Severe Endometriosis II-15
Treatment for Ovarian Endometriosis II-15
Surgical Vs. Medicinal Interventions II-16
Medicinal Interventions II-16
Advantages II-16
Disadvantages II-16
Surgery II-16
Advantages II-16
Disadvantages II-16
In-vitro Fertilization II-16
Other Treatment II-17
3. PRODUCT OVERVIEW II-18
Endometriosis - An Overview II-18
Occurrence of Endometriosis in Women II-18
Causes and Symptoms II-19
Causes II-19
Estrogen Theory II-19
Müllerianosis Theory II-19
Retrograde Menstruation Theory II-19
Coelomic Metaplasia Theory II-20
Hereditary Factors II-20
Environmental Factors II-20
Dioxin Behavior in the Body II-21
Birth Defects II-21
Other Causes II-21
Symptoms of Endometriosis II-21
Reasons for Pain due to Endometriosis II-22
Endometriosis and Infertility II-22
Kinds of Endometriosis II-23
Reproductive Area Endometriosis II-23
Uterosacral/Presacral Nerve Endometriosis II-23
Cul-de-Sac ("Pouch of Douglas") Endometriosis II-23
Gastrointestinal Endometriosis II-23
Pleural (lung/chest cavity/diaphragmatic) Endometriosis II-23
Urinary Tract (kidneys, ureters, bladder and urethra)
Endometriosis II-23
Skin Endometriosis II-23
Stages of Endometriosis II-23
Diagnosis of Endometriosis II-24
Major Diagnostic Techniques II-24
Pelvic Exam II-24
Laparoscopy II-24
Other Diagnostic Procedures II-25
A New Non-invasive Test for the Diagnosis of Endometriosis II-25
Endometriosis Markers II-25
Counseling of patients II-25
Recurrence of Endometriosis II-25
Endometriosis & Infertility II-26
Miscarriage II-26
Endometriosis & Thyroid Autoimmunity II-26
Relationship between Endometriosis and Autoimmune Disease II-26
Endometriosis & Cancer II-26
Associations & Research Centers II-27
The Endometriosis Association II-27
Endometriosis Research Center II-27
4. A REVIEW OF SELECT CLINICAL TRIALS II-28
Neurocrine Biosciences Announces Positive Results of Phase II
Daisy PETAL Study with Elagolix II-28
Repros Therapeutics to Conduct Phase II Study with Five Doses
of Proellex II-28
Neurocrine Biosciences Announces Results from Elagolix's Phase
II Tulip PETAL Study II-29
Repros Therapeutics Announces Positive Results from Proellex's
Phase II Clinical Study II-29
Q Chip Conducts Pre-Clinical Trial for Biosimilar Q-
Leuprolide, Indicated for Endometriosis and Prostrate Cancer II-30
5. RECENT INDUSTRY ACTIVITY II-31
Neurocrine and Abbott International Enter Into Collaboration
Deal for Elagolix II-31
Meditrina's MPI-676 Bags US Patents for Endometriosis Treatment II-31
Claire Ellen Products Rolls Out ProSirona, an Endometriotic
Pain-Relieving Drug II-31
Bayer Schering and Protagen Sign Collaborative Contract to
Develop New Biomarkers for Endometriosis II-32
Gedeon Richter Acquires PregLem Holding II-32
PregLem Signs In-Licensing Deal with Merck Serono II-32
BMP Sunstone to Market Pfizer's Depo-Provera in China II-33
Cryo-Cell International Signs Exclusive License Deal with
Cryopraxis Cryobiology II-33
St. Joseph's Hospital and Medical Center Signs Deal with
InNexus Biotechnology II-34
Cryo-Cell International and Cryopraxis Cryobiology Ink R&D Deal II-34
MIT to Establish Endometriosis Investigation Center II-35
Alfresa Pharma Signs Letter of Intent with Nobelpharma II-35
Ardana Secures USFDA Approval for Clinical Development of
Teverelix LA II-35
AEterna Zentaris Announces Termination of License and
Cooperation Agreement with Solvay Pharmaceuticals for
Cetrorelix II-36
6. FOCUS ON SELECT GLOBAL PLAYERS II-37
Abbott Laboratories (USA) II-37
AEterna Zentaris, Inc. (Canada) II-37
AstraZeneca Plc. (UK) II-37
Bayer HealthCare Pharmaceuticals, Inc. (USA) II-38
Eli Lilly and Company (USA) II-38
Meditrina Pharmaceuticals, Inc. (US) II-38
Neurocrine Biosciences, Inc. (US) II-39
Pfizer, Inc. (US) II-39
Repros Therapeutics, Inc. (US) II-40
7. GLOBAL MARKET PERSPECTIVE II-41
Table 1: World Recent Past, Current and Future Analysis for
Endometriosis by Geographic Region - US, Canada, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) II-41
Table 2: World Historic Review for Endometriosis by Geographic
Region - US, Canada, Japan, Europe, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-42
Table 3: World 15-Year Perspective for Endometriosis by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, and Rest of World Markets for Years
2003, 2011 and 2017 (includes corresponding Graph/Chart) II-43
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Endometriosis in the US III-1
Endometriosis' Research Initiatives Undertaken in the US III-1
Regulatory Moves III-2
Clinical Trials III-2
Strategic Corporate Developments III-4
Select Key Players III-6
B.Market Analytics III-10
Table 4: US Recent Past, Current and Future Analysis for
Endometriosis with Annual Sales Figures in US$ Million for
Years 2009 through 2017 (includes corresponding Graph/Chart) III-10
Table 5: US Historic Review for Endometriosis with Annual
Sales Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) III-11
2. CANADA III-12
A.Market Analysis III-12
Select Key Players III-12
B.Market Analytics III-12
Table 6: Canadian Recent Past, Current and Future Analysis
for Endometriosis with Annual Sales Figures in US$ Million
for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-12
Table 7: Canadian Historic Review for Endometriosis with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-13
3. JAPAN III-14
A.Market Analysis III-14
Select Key Player III-14
B.Market Analytics III-15
Table 8: Japanese Recent Past, Current and Future Analysis
for Endometriosis with Annual Sales Figures in US$ Million
for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-15
Table 9: Japanese Historic Review for Endometriosis with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-16
4. EUROPE III-17
A.Market Analysis III-17
Endometriosis in Europe III-17
Market Prospects III-17
Strategic Corporate Developments III-17
B.Market Analytics III-19
Table 10: European Recent Past, Current & Future Analysis
for Endometriosis by Geographic Region - France, Germany,
Italy, UK, Spain, and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) III-19
Table 11: European Historic Review for Endometriosis by
Geographic Region - France, Germany, Italy, UK, Spain, and
Rest of Europe Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) III-20
Table 12: European 15-Year Perspective for Endometriosis by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, UK, Spain, and Rest of Europe
Markets for Years 2003, 2011 and 2017 (includes
corresponding Graph/Chart) III-21
4a. FRANCE III-22
Market Analytics III-22
Table 13: French Recent Past, Current & Future Analysis for
Endometriosis with Annual Sales Figures in US$ Million for
Years 2009 through 2017 (includes corresponding Graph/Chart) III-22
Table 14: French Historic Review for Endometriosis with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-23
4b. GERMANY III-24
A.Market Analysis III-24
EAPP in Germany III-24
B.Market Analytics III-24
Table 15: German Recent Past, Current & Future Analysis for
Endometriosis with Annual Sales Figures in US$ Million for
Years 2009 through 2017 (includes corresponding Graph/Chart) III-24
Table 16: German Historic Review for Endometriosis with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-25
4c. ITALY III-26
Market Analytics III-26
Table 17: Italian Recent Past, Current & Future Analysis for
Endometriosis with Annual Sales Figures in US$ Million for
Years 2009 through 2017 (includes corresponding Graph/Chart) III-26
Table 18: Italian Historic Review for Endometriosis with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-27
4d. THE UNITED KINGDOM III-28
A.Market Analysis III-28
Endometriosis in the UK III-28
Clinical Trial III-28
AstraZeneca Plc - A Key Player III-29
B.Market Analytics III-29
Table 19: UK Recent Past, Current & Future Analysis for
Endometriosis with Annual Sales Figures in US$ Million for
Years 2009 through 2017 (includes corresponding Graph/Chart) III-29
Table 20: UK Historic Review for Endometriosis with Annual
Sales Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) III-30
4e. SPAIN III-31
Market Analytics III-31
Table 21: Spanish Recent Past, Current & Future Analysis for
Endometriosis with Annual Sales Figures in US$ Million for
Years 2009 through 2017 (includes corresponding Graph/Chart) III-31
Table 22: Spanish Historic Review for Endometriosis with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-32
4f. REST OF EUROPE III-33
Market Analytics III-33
Table 23: Rest of Europe Recent Past, Current & Future
Analysis for Endometriosis with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-33
Table 24: Rest of Europe Historic Review for Endometriosis
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-34
5. REST OF WORLD III-35
A.Market Analysis III-35
Asia-Pacific - Growing Acceptance of Herbal Treatment III-35
Strategic Corporate Developments III-35
B.Market Analytics III-38
Table 25: Rest of World Recent Past, Current and Future
Analysis for Endometriosis Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-38
Table 26: Rest of World Historic Review for Endometriosis
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-39
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 32 (including Divisions/Subsidiaries - 38)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 15
Canada 3
Japan 4
Europe 12
Germany 2
The United Kingdom 3
Rest of Europe 7
Asia-Pacific (Excluding Japan) 4
------------------------------------------
To order this report:
Pathology Industry: Global Endometriosis Industry
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article